Xembify (immune globulin human-klhw)

Overview

immune globulin

immunoglobulin

• immunomodulatory effects (immune globulin)
• nephrotoxicity
• thrombogenic effects

• monitor renal fxn; nephrotoxicity risk may be higher w/ sucrose-containing immune globulins, may vary depending on route of admin.

Contraindicated

• cidofovir
Xembify (immune globulin human-klhw) (immune globulin (human))

+

cidofovir

1 interaction

Contraindicated

immune globulin + cidofovir

contraindicated; D/C immune globulin at least 7 days prior to cidofovir tx: combo may incr. cidofovir levels, risk of myelosuppression, nephrotoxicity, other adverse effects (additive effects)

Avoid/Use Alternative

• aldesleukin
Xembify (immune globulin human-klhw) (immune globulin (human))

+

aldesleukin

1 interaction

Avoid/Use Alternative

immune globulin + aldesleukin

use alternative or monitor renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity (additive effects)

• amikacin
Xembify (immune globulin human-klhw) (immune globulin (human))

+

amikacin

1 interaction

Avoid/Use Alternative

immune globulin + amikacin

use alternative or monitor amikacin levels, renal fxn, ototoxicity; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. amikacin levels, risk of nephrotoxicity, auditory, vestibular, other adverse effects (additive effects)

• amikacin inhaled
Xembify (immune globulin human-klhw) (immune globulin (human))

+

amikacin inhaled

1 interaction

Avoid/Use Alternative

immune globulin + amikacin inhaled

use alternative or monitor renal fxn, ototoxicity; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. amikacin levels, risk of nephrotoxicity, auditory, vestibular, other adverse effects (additive effects)

• bumetanide
Xembify (immune globulin human-klhw) (immune globulin (human))

+

bumetanide

1 interaction

Avoid/Use Alternative

immune globulin + bumetanide

use alternative or monitor renal fxn, thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity, thromboembolism (additive effects)

• clofarabine
Xembify (immune globulin human-klhw) (immune globulin (human))

+

clofarabine

1 interaction

Avoid/Use Alternative

immune globulin + clofarabine

avoid immune globulin during 5 day clofarabine tx; monitor CBC, renal fxn, BP; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. clofarabine levels, risk of serious infection, myelosuppression, nephrotoxicity, hypotension, other adverse effects (additive effects)

• efgartigimod alfa
Xembify (immune globulin human-klhw) (immune globulin (human))

+

efgartigimod alfa

1 interaction

Avoid/Use Alternative

immune globulin + efgartigimod alfa

consider alternative if long-term use: combo may decr. immune globulin levels, efficacy (FcRn blockade)

• ethacrynic acid
Xembify (immune globulin human-klhw) (immune globulin (human))

+

ethacrynic acid

1 interaction

Avoid/Use Alternative

immune globulin + ethacrynic acid

use alternative or monitor renal fxn, thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity, thromboembolism (additive effects)

• foscarnet
Xembify (immune globulin human-klhw) (immune globulin (human))

+

foscarnet

1 interaction

Avoid/Use Alternative

immune globulin + foscarnet

use alternative or monitor CBC, renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. foscarnet levels, risk of myelosuppression, nephrotoxicity, other adverse effects (additive effects)

• furosemide
Xembify (immune globulin human-klhw) (immune globulin (human))

+

furosemide

1 interaction

Avoid/Use Alternative

immune globulin + furosemide

use alternative or monitor renal fxn, thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity, thromboembolism (additive effects)

• ganciclovir
Xembify (immune globulin human-klhw) (immune globulin (human))

+

ganciclovir

1 interaction

Avoid/Use Alternative

immune globulin + ganciclovir

use alternative or monitor CBC, renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. ganciclovir levels, risk of myelosuppression, nephrotoxicity, other adverse effects (additive effects)

• gentamicin
Xembify (immune globulin human-klhw) (immune globulin (human))

+

gentamicin

1 interaction

Avoid/Use Alternative

immune globulin + gentamicin

use alternative or monitor gentamicin levels, renal fxn, ototoxicity; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. gentamicin levels, risk of nephrotoxicity, auditory, vestibular, other adverse effects (additive effects)

• immune globulin
Xembify (immune globulin human-klhw) (immune globulin (human))

+

immune globulin

1 interaction

Avoid/Use Alternative

immune globulin + immune globulin

avoid combo: combo may incr. risk of nephrotoxicity, thromboembolism, other adverse effects (additive effects, duplicate tx)

• mannitol
Xembify (immune globulin human-klhw) (immune globulin (human))

+

mannitol

1 interaction

Avoid/Use Alternative

immune globulin + mannitol

use alternative or monitor renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. mannitol levels, risk of nephrotoxicity, neurotoxicity (incl. life-threatening), other adverse effects (additive effects)

• methotrexate
Xembify (immune globulin human-klhw) (immune globulin (human))

+

methotrexate

1 interaction

Avoid/Use Alternative

immune globulin + methotrexate

consider alternative or monitor CBC, renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. methotrexate levels, risk of serious infection, myelosuppression, nephrotoxicity, other adverse effects (additive effects)

• oxaliplatin
Xembify (immune globulin human-klhw) (immune globulin (human))

+

oxaliplatin

1 interaction

Avoid/Use Alternative

immune globulin + oxaliplatin

use alternative or monitor ECG, CBC, renal fxn, ototoxicity; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. oxaliplatin levels, risk of QT prolongation, cardiac arrhythmias, serious infection, myelosuppression, nephrotoxicity, auditory, vestibular, other adverse effects (additive effects)

• pentamidine
Xembify (immune globulin human-klhw) (immune globulin (human))

+

pentamidine

1 interaction

Avoid/Use Alternative

immune globulin + pentamidine

use alternative or monitor renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity (additive effects)

• polymyxin B
Xembify (immune globulin human-klhw) (immune globulin (human))

+

polymyxin B

1 interaction

Avoid/Use Alternative

immune globulin + polymyxin B

avoid combo: combo may incr. risk of nephrotoxicity (additive effects)

• pozelimab
Xembify (immune globulin human-klhw) (immune globulin (human))

+

pozelimab

1 interaction

Avoid/Use Alternative

immune globulin + pozelimab

use alternative: combo may decr. pozelimab levels, efficacy (FcRn blockade)

• rozanolixizumab
Xembify (immune globulin human-klhw) (immune globulin (human))

+

rozanolixizumab

1 interaction

Avoid/Use Alternative

immune globulin + rozanolixizumab

consider alternative if long-term use: combo may decr. immune globulin levels, efficacy (FcRn blockade)

• streptomycin
Xembify (immune globulin human-klhw) (immune globulin (human))

+

streptomycin

1 interaction

Avoid/Use Alternative

immune globulin + streptomycin

use alternative or monitor renal fxn, ototoxicity; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. streptomycin levels, risk of nephrotoxicity, auditory, vestibular, other adverse effects (additive effects)

• streptozocin
Xembify (immune globulin human-klhw) (immune globulin (human))

+

streptozocin

1 interaction

Avoid/Use Alternative

immune globulin + streptozocin

use alternative or monitor renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity (additive effects)

• tenofovir disoproxil
Xembify (immune globulin human-klhw) (immune globulin (human))

+

tenofovir disoproxil

1 interaction

Avoid/Use Alternative

immune globulin + tenofovir disoproxil

use alternative or monitor renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. tenofovir levels, risk of nephrotoxicity, other adverse effects (additive effects)

• tobramycin
Xembify (immune globulin human-klhw) (immune globulin (human))

+

tobramycin

1 interaction

Avoid/Use Alternative

immune globulin + tobramycin

use alternative or monitor tobramycin levels, renal fxn, ototoxicity; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. tobramycin levels, risk of nephrotoxicity, auditory, vestibular, other adverse effects (additive effects)

• tobramycin inhaled
Xembify (immune globulin human-klhw) (immune globulin (human))

+

tobramycin inhaled

1 interaction

Avoid/Use Alternative

immune globulin + tobramycin inhaled

use alternative or monitor renal fxn, ototoxicity; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. tobramycin levels, risk of nephrotoxicity, auditory, vestibular, other adverse effects (additive effects)

• torsemide
Xembify (immune globulin human-klhw) (immune globulin (human))

+

torsemide

1 interaction

Avoid/Use Alternative

immune globulin + torsemide

use alternative or monitor renal fxn, thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity, thromboembolism (additive effects)

• tranexamic acid
Xembify (immune globulin human-klhw) (immune globulin (human))

+

tranexamic acid

1 interaction

Avoid/Use Alternative

immune globulin + tranexamic acid

avoid combo: combo may incr. risk of thromboembolism (additive effects)

• vaccinia immune globulin
Xembify (immune globulin human-klhw) (immune globulin (human))

+

vaccinia immune globulin

1 interaction

Avoid/Use Alternative

immune globulin + vaccinia immune globulin

use alternative or monitor thrombosis s/sx, renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism, nephrotoxicity (additive effects)

• valganciclovir
Xembify (immune globulin human-klhw) (immune globulin (human))

+

valganciclovir

1 interaction

Avoid/Use Alternative

immune globulin + valganciclovir

use alternative or monitor CBC, renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. valganciclovir levels, risk of myelosuppression, nephrotoxicity, other adverse effects (additive effects)

Monitor/Modify Tx

• abemaciclib
Xembify (immune globulin human-klhw) (immune globulin (human))

+

abemaciclib

1 interaction

Monitor/Modify Tx

immune globulin + abemaciclib

monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

• abrocitinib
Xembify (immune globulin human-klhw) (immune globulin (human))

+

abrocitinib

1 interaction

Monitor/Modify Tx

immune globulin + abrocitinib

monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

• acyclovir
Xembify (immune globulin human-klhw) (immune globulin (human))

+

acyclovir

1 interaction

Monitor/Modify Tx

immune globulin + acyclovir

monitor renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. acyclovir levels, risk of nephrotoxicity, other adverse effects (additive effects)

• adefovir dipivoxil
Xembify (immune globulin human-klhw) (immune globulin (human))

+

adefovir dipivoxil

1 interaction

Monitor/Modify Tx

immune globulin + adefovir dipivoxil

monitor renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. adefovir levels, risk of nephrotoxicity, other adverse effects (renal excretion decreased by nephrotoxic agents, additive effects)

• adenovirus vaccine, live
Xembify (immune globulin human-klhw) (immune globulin (human))

+

adenovirus vaccine, live

1 interaction

Monitor/Modify Tx

immune globulin + adenovirus vaccine, live

consider vaccinating at least 2wk before or 8-11mo after IVIG tx; if vaccine given shortly before IVIG, consider re-vaccination: combo may result in inadequate vaccine response (antagonistic effects)

• aflibercept
Xembify (immune globulin human-klhw) (immune globulin (human))

+

aflibercept

1 interaction

Monitor/Modify Tx

immune globulin + aflibercept

monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

• alectinib
Xembify (immune globulin human-klhw) (immune globulin (human))

+

alectinib

1 interaction

Monitor/Modify Tx

immune globulin + alectinib

monitor renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity (additive effects)

• aliskiren
Xembify (immune globulin human-klhw) (immune globulin (human))

+

aliskiren

1 interaction

Monitor/Modify Tx

immune globulin + aliskiren

monitor renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity (additive effects)

• amiloride
Xembify (immune globulin human-klhw) (immune globulin (human))

+

amiloride

1 interaction

Monitor/Modify Tx

immune globulin + amiloride

monitor renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity (additive effects)

• aminocaproic acid
Xembify (immune globulin human-klhw) (immune globulin (human))

+

aminocaproic acid

1 interaction

Monitor/Modify Tx

immune globulin + aminocaproic acid

monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

• amphotericin
Xembify (immune globulin human-klhw) (immune globulin (human))

+

amphotericin

1 interaction

Monitor/Modify Tx

immune globulin + amphotericin

monitor renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity (additive effects)

• angiotensin II
Xembify (immune globulin human-klhw) (immune globulin (human))

+

angiotensin II

1 interaction

Monitor/Modify Tx

immune globulin + angiotensin II

monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

• anthrax immune globulin
Xembify (immune globulin human-klhw) (immune globulin (human))

+

anthrax immune globulin

1 interaction

Monitor/Modify Tx

immune globulin + anthrax immune globulin

monitor renal fxn, thrombosis s/sx; use lowest immune globulin dose, concentration, and infusion rate possible: combo may incr. risk of nephrotoxicity, thromboembolism (additive effects)

• anti-inhibitor coagulant complex
Xembify (immune globulin human-klhw) (immune globulin (human))

+

anti-inhibitor coagulant complex

1 interaction

Monitor/Modify Tx

immune globulin + anti-inhibitor coagulant complex

monitor thrombosis s/sx, especially w/ anti-inhibitor coagulant complex dose >100 units/kg; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

• antihemophilic factor (factor VIII)/von Willebrand factor complex
Xembify (immune globulin human-klhw) (immune globulin (human))

+

antihemophilic factor (factor VIII)/ von Willebrand factor complex

1 interaction

Monitor/Modify Tx

immune globulin + antihemophilic factor (factor VIII)/ von Willebrand factor complex

monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

• asciminib
Xembify (immune globulin human-klhw) (immune globulin (human))

+

asciminib

1 interaction

Monitor/Modify Tx

immune globulin + asciminib

monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

• asparaginase
Xembify (immune globulin human-klhw) (immune globulin (human))

+

asparaginase

1 interaction

Monitor/Modify Tx

immune globulin + asparaginase

monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

• aspirin
Xembify (immune globulin human-klhw) (immune globulin (human))

+

aspirin

1 interaction

Monitor/Modify Tx

immune globulin + aspirin

monitor renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity (additive effects)

• atidarsagene autotemcel
Xembify (immune globulin human-klhw) (immune globulin (human))

+

atidarsagene autotemcel

1 interaction

Monitor/Modify Tx

immune globulin + atidarsagene autotemcel

monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

• auranofin
Xembify (immune globulin human-klhw) (immune globulin (human))

+

auranofin

1 interaction

Monitor/Modify Tx

immune globulin + auranofin

monitor renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. auranofin levels, risk of nephrotoxicity, other adverse effects (additive effects)

• avatrombopag
Xembify (immune globulin human-klhw) (immune globulin (human))

+

avatrombopag

1 interaction

Monitor/Modify Tx

immune globulin + avatrombopag

monitor platelets, thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

• axitinib
Xembify (immune globulin human-klhw) (immune globulin (human))

+

axitinib

1 interaction

Monitor/Modify Tx

immune globulin + axitinib

monitor renal fxn, thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity, thromboembolism (additive effects)

• azilsartan medoxomil
Xembify (immune globulin human-klhw) (immune globulin (human))

+

azilsartan medoxomil

1 interaction

Monitor/Modify Tx

immune globulin + azilsartan medoxomil

monitor renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity (additive effects)

• balsalazide
Xembify (immune globulin human-klhw) (immune globulin (human))

+

balsalazide

1 interaction

Monitor/Modify Tx

immune globulin + balsalazide

monitor renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity (additive effects)

• baricitinib
Xembify (immune globulin human-klhw) (immune globulin (human))

+

baricitinib

1 interaction

Monitor/Modify Tx

immune globulin + baricitinib

monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

• bazedoxifene
Xembify (immune globulin human-klhw) (immune globulin (human))

+

bazedoxifene

1 interaction

Monitor/Modify Tx

immune globulin + bazedoxifene

monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

• benazepril
Xembify (immune globulin human-klhw) (immune globulin (human))

+

benazepril

1 interaction

Monitor/Modify Tx

immune globulin + benazepril

monitor renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity (additive effects)

• bevacizumab
Xembify (immune globulin human-klhw) (immune globulin (human))

+

bevacizumab

1 interaction

Monitor/Modify Tx

immune globulin + bevacizumab

monitor renal fxn, thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity, thromboembolism (additive effects)

• binimetinib
Xembify (immune globulin human-klhw) (immune globulin (human))

+

binimetinib

1 interaction

Monitor/Modify Tx

immune globulin + binimetinib

monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

• bleomycin
Xembify (immune globulin human-klhw) (immune globulin (human))

+

bleomycin

1 interaction

Monitor/Modify Tx

immune globulin + bleomycin

monitor renal fxn; decr. bleomycin dose based on CrCl: combo may incr. bleomycin levels, risk of pulmonary toxicities (incl. life-threatening), other adverse effects (renal excretion decreased)

• botulism immune globulin
Xembify (immune globulin human-klhw) (immune globulin (human))

+

botulism immune globulin

1 interaction

Monitor/Modify Tx

immune globulin + botulism immune globulin

monitor renal fxn, thrombosis s/sx; use lowest effective dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity, thromboembolism (additive effects)

• brolucizumab
Xembify (immune globulin human-klhw) (immune globulin (human))

+

brolucizumab

1 interaction

Monitor/Modify Tx

immune globulin + brolucizumab

monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

• C1 esterase inhibitor
Xembify (immune globulin human-klhw) (immune globulin (human))

+

C1 esterase inhibitor

1 interaction

Monitor/Modify Tx

immune globulin + C1 esterase inhibitor

monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

• cabozantinib
Xembify (immune globulin human-klhw) (immune globulin (human))

+

cabozantinib

1 interaction

Monitor/Modify Tx

immune globulin + cabozantinib

monitor renal fxn, thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity, thromboembolism (additive effects)

• calaspargase
Xembify (immune globulin human-klhw) (immune globulin (human))

+

calaspargase

1 interaction

Monitor/Modify Tx

immune globulin + calaspargase

monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

• candesartan cilexetil
Xembify (immune globulin human-klhw) (immune globulin (human))

+

candesartan cilexetil

1 interaction

Monitor/Modify Tx

immune globulin + candesartan cilexetil

monitor renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity (additive effects)

• capecitabine
Xembify (immune globulin human-klhw) (immune globulin (human))

+

capecitabine

1 interaction

Monitor/Modify Tx

immune globulin + capecitabine

monitor renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity (additive effects)

• captopril
Xembify (immune globulin human-klhw) (immune globulin (human))

+

captopril

1 interaction

Monitor/Modify Tx

immune globulin + captopril

monitor renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity (additive effects)

• carboplatin
Xembify (immune globulin human-klhw) (immune globulin (human))

+

carboplatin

1 interaction

Monitor/Modify Tx

immune globulin + carboplatin

monitor CBC, renal fxn, ototoxicity; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. carboplatin levels, risk of serious infection, myelosuppression, nephrotoxicity, auditory, vestibular, other adverse effects (additive effects)

• carfilzomib
Xembify (immune globulin human-klhw) (immune globulin (human))

+

carfilzomib

1 interaction

Monitor/Modify Tx

immune globulin + carfilzomib

monitor renal fxn, thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity, thromboembolism (additive effects)

• celecoxib
Xembify (immune globulin human-klhw) (immune globulin (human))

+

celecoxib

1 interaction

Monitor/Modify Tx

immune globulin + celecoxib

monitor renal fxn, thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity, thromboembolism (additive effects)

• chlorothiazide
Xembify (immune globulin human-klhw) (immune globulin (human))

+

chlorothiazide

1 interaction

Monitor/Modify Tx

immune globulin + chlorothiazide

monitor renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity (additive effects)

• chlorthalidone
Xembify (immune globulin human-klhw) (immune globulin (human))

+

chlorthalidone

1 interaction

Monitor/Modify Tx

immune globulin + chlorthalidone

monitor renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity (additive effects)

• chorionic gonadotropin
Xembify (immune globulin human-klhw) (immune globulin (human))

+

chorionic gonadotropin

1 interaction

Monitor/Modify Tx

immune globulin + chorionic gonadotropin

monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

• cisplatin
Xembify (immune globulin human-klhw) (immune globulin (human))

+

cisplatin

1 interaction

Monitor/Modify Tx

immune globulin + cisplatin

monitor CBC, renal fxn, ototoxicity; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. cisplatin levels, risk of serious infection, myelosuppression, nephrotoxicity, auditory, vestibular, other adverse effects (additive effects)

• clindamycin
Xembify (immune globulin human-klhw) (immune globulin (human))

+

clindamycin

1 interaction

Monitor/Modify Tx

immune globulin + clindamycin

monitor renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity (additive effects)

• clozapine
Xembify (immune globulin human-klhw) (immune globulin (human))

+

clozapine

1 interaction

Monitor/Modify Tx

immune globulin + clozapine

monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

• coagulation factor IX
Xembify (immune globulin human-klhw) (immune globulin (human))

+

coagulation factor IX

1 interaction

Monitor/Modify Tx

immune globulin + coagulation factor IX

monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

• coagulation factor VIIa
Xembify (immune globulin human-klhw) (immune globulin (human))

+

coagulation factor VIIa

1 interaction

Monitor/Modify Tx

immune globulin + coagulation factor VIIa

monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

• coagulation factor XIII A-subunit
Xembify (immune globulin human-klhw) (immune globulin (human))

+

coagulation factor XIII A-subunit

1 interaction

Monitor/Modify Tx

immune globulin + coagulation factor XIII A-subunit

monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

• colistimethate
Xembify (immune globulin human-klhw) (immune globulin (human))

+

colistimethate

1 interaction

Monitor/Modify Tx

immune globulin + colistimethate

monitor renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. colistimethate levels, risk of nephrotoxicity, other adverse effects (additive effects)

• concizumab
Xembify (immune globulin human-klhw) (immune globulin (human))

+

concizumab

1 interaction

Monitor/Modify Tx

immune globulin + concizumab

monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

• creatine
Xembify (immune globulin human-klhw) (immune globulin (human))

+

creatine

1 interaction

Monitor/Modify Tx

immune globulin + creatine

monitor renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity (additive effects)

• cyclophosphamide
Xembify (immune globulin human-klhw) (immune globulin (human))

+

cyclophosphamide

1 interaction

Monitor/Modify Tx

immune globulin + cyclophosphamide

monitor CBC, renal, cardiac fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. cyclophosphamide levels, risk of serious infection, myelosuppression, nephrotoxicity, cardiotoxicity, other adverse effects (additive effects)

• cyclosporine
Xembify (immune globulin human-klhw) (immune globulin (human))

+

cyclosporine

1 interaction

Monitor/Modify Tx

immune globulin + cyclosporine

monitor renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity (additive effects)

• cytomegalovirus immune globulin
Xembify (immune globulin human-klhw) (immune globulin (human))

+

cytomegalovirus immune globulin

1 interaction

Monitor/Modify Tx

immune globulin + cytomegalovirus immune globulin

monitor renal fxn, thrombosis s/sx; use lowest effective dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity, thromboembolism (additive effects)

• danazol
Xembify (immune globulin human-klhw) (immune globulin (human))

+

danazol

1 interaction

Monitor/Modify Tx

immune globulin + danazol

monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

• darbepoetin alfa
Xembify (immune globulin human-klhw) (immune globulin (human))

+

darbepoetin alfa

1 interaction

Monitor/Modify Tx

immune globulin + darbepoetin alfa

monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

• deferasirox
Xembify (immune globulin human-klhw) (immune globulin (human))

+

deferasirox

1 interaction

Monitor/Modify Tx

immune globulin + deferasirox

monitor CBC, renal fxn, ototoxicity; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. deferasirox levels, risk of myelosuppression, nephrotoxicity, auditory, vestibular, other adverse effects (additive effects)

• deferoxamine
Xembify (immune globulin human-klhw) (immune globulin (human))

+

deferoxamine

1 interaction

Monitor/Modify Tx

immune globulin + deferoxamine

monitor renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity (additive effects)

• deflazacort
Xembify (immune globulin human-klhw) (immune globulin (human))

+

deflazacort

1 interaction

Monitor/Modify Tx

immune globulin + deflazacort

monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

• dengue vaccine, live
Xembify (immune globulin human-klhw) (immune globulin (human))

+

dengue vaccine, live

1 interaction

Monitor/Modify Tx

immune globulin + dengue vaccine, live

consider vaccinating at least 2wk before or 8-11mo after IVIG tx; if vaccine given shortly before IVIG, consider re-vaccination: combo may result in inadequate vaccine response (antagonistic effects)

• desogestrel (contraceptive)
Xembify (immune globulin human-klhw) (immune globulin (human))

+

desogestrel (contraceptive)

1 interaction

Monitor/Modify Tx

immune globulin + desogestrel (contraceptive)

monitor thrombosis s/sx, especially w/ concomitant estrogen use; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

• deuruxolitinib
Xembify (immune globulin human-klhw) (immune globulin (human))

+

deuruxolitinib

1 interaction

Monitor/Modify Tx

immune globulin + deuruxolitinib

monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

• dexamethasone
Xembify (immune globulin human-klhw) (immune globulin (human))

+

dexamethasone

1 interaction

Monitor/Modify Tx

immune globulin + dexamethasone

monitor thrombosis s/sx, especially if multiple myeloma use; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

• diclofenac
Xembify (immune globulin human-klhw) (immune globulin (human))

+

diclofenac

1 interaction

Monitor/Modify Tx

immune globulin + diclofenac

monitor renal fxn, thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible; use lowest effective diclofenac dose, shortest effective tx duration: combo may incr. risk of nephrotoxicity, thromboembolism (additive effects)

• diclofenac topical
Xembify (immune globulin human-klhw) (immune globulin (human))

+

diclofenac topical

1 interaction

Monitor/Modify Tx

immune globulin + diclofenac topical

monitor renal fxn, thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible; use lowest effective diclofenac dose, shortest effective tx duration: combo may incr. risk of nephrotoxicity, thromboembolism (additive effects)

• dienogest (contraceptive)
Xembify (immune globulin human-klhw) (immune globulin (human))

+

dienogest (contraceptive)

1 interaction

Monitor/Modify Tx

immune globulin + dienogest (contraceptive)

monitor thrombosis s/sx, especially w/ concomitant estrogen use; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

• diflunisal
Xembify (immune globulin human-klhw) (immune globulin (human))

+

diflunisal

1 interaction

Monitor/Modify Tx

immune globulin + diflunisal

monitor renal fxn, thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible; use lowest effective diflunisal dose, shortest effective tx duration: combo may incr. risk of nephrotoxicity, thromboembolism (additive effects)

• drospirenone (contraceptive)
Xembify (immune globulin human-klhw) (immune globulin (human))

+

drospirenone (contraceptive)

1 interaction

Monitor/Modify Tx

immune globulin + drospirenone (contraceptive)

monitor thrombosis s/sx, especially w/ concomitant estrogen use; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

• drospirenone (hormone replacement)
Xembify (immune globulin human-klhw) (immune globulin (human))

+

drospirenone (hormone replacement)

1 interaction

Monitor/Modify Tx

immune globulin + drospirenone (hormone replacement)

monitor thrombosis s/sx, especially w/ concomitant estrogen use; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

• eltrombopag
Xembify (immune globulin human-klhw) (immune globulin (human))

+

eltrombopag

1 interaction

Monitor/Modify Tx

immune globulin + eltrombopag

monitor platelets, thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

• enalapril
Xembify (immune globulin human-klhw) (immune globulin (human))

+

enalapril

1 interaction

Monitor/Modify Tx

immune globulin + enalapril

monitor renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity (additive effects)

• enalaprilat
Xembify (immune globulin human-klhw) (immune globulin (human))

+

enalaprilat

1 interaction

Monitor/Modify Tx

immune globulin + enalaprilat

monitor renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity (additive effects)

• epirubicin
Xembify (immune globulin human-klhw) (immune globulin (human))

+

epirubicin

1 interaction

Monitor/Modify Tx

immune globulin + epirubicin

monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

• epoetin alfa
Xembify (immune globulin human-klhw) (immune globulin (human))

+

epoetin alfa

1 interaction

Monitor/Modify Tx

immune globulin + epoetin alfa

monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

• estetrol (contraceptive)
Xembify (immune globulin human-klhw) (immune globulin (human))

+

estetrol (contraceptive)

1 interaction

Monitor/Modify Tx

immune globulin + estetrol (contraceptive)

monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

• estradiol (contraceptive)
Xembify (immune globulin human-klhw) (immune globulin (human))

+

estradiol (contraceptive)

1 interaction

Monitor/Modify Tx

immune globulin + estradiol (contraceptive)

monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

• estradiol (hormone replacement)
Xembify (immune globulin human-klhw) (immune globulin (human))

+

estradiol (hormone replacement)

1 interaction

Monitor/Modify Tx

immune globulin + estradiol (hormone replacement)

monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

• estrogens, conjugated (hormone replacement)
Xembify (immune globulin human-klhw) (immune globulin (human))

+

estrogens, conjugated (hormone replacement)

1 interaction

Monitor/Modify Tx

immune globulin + estrogens, conjugated (hormone replacement)

monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

• estrogens, esterified (hormone replacement)
Xembify (immune globulin human-klhw) (immune globulin (human))

+

estrogens, esterified (hormone replacement)

1 interaction

Monitor/Modify Tx

immune globulin + estrogens, esterified (hormone replacement)

monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

• ethinyl estradiol (contraceptive)
Xembify (immune globulin human-klhw) (immune globulin (human))

+

ethinyl estradiol (contraceptive)

1 interaction

Monitor/Modify Tx

immune globulin + ethinyl estradiol (contraceptive)

monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

• ethinyl estradiol (hormone replacement)
Xembify (immune globulin human-klhw) (immune globulin (human))

+

ethinyl estradiol (hormone replacement)

1 interaction

Monitor/Modify Tx

immune globulin + ethinyl estradiol (hormone replacement)

monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

• ethynodiol (contraceptive)
Xembify (immune globulin human-klhw) (immune globulin (human))

+

ethynodiol (contraceptive)

1 interaction

Monitor/Modify Tx

immune globulin + ethynodiol (contraceptive)

monitor thrombosis s/sx, especially w/ concomitant estrogen use; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

• etodolac
Xembify (immune globulin human-klhw) (immune globulin (human))

+

etodolac

1 interaction

Monitor/Modify Tx

immune globulin + etodolac

monitor renal fxn, thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible; use lowest effective etodolac dose, shortest effective tx duration: combo may incr. risk of nephrotoxicity, thromboembolism (additive effects)

• etonogestrel (contraceptive)
Xembify (immune globulin human-klhw) (immune globulin (human))

+

etonogestrel (contraceptive)

1 interaction

Monitor/Modify Tx

immune globulin + etonogestrel (contraceptive)

monitor thrombosis s/sx, especially w/ concomitant estrogen use; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

• everolimus
Xembify (immune globulin human-klhw) (immune globulin (human))

+

everolimus

1 interaction

Monitor/Modify Tx

immune globulin + everolimus

monitor renal fxn, thrombosis s/sx especially if immunosuppressant use; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity, thromboembolism (additive effects)

• exenatide
Xembify (immune globulin human-klhw) (immune globulin (human))

+

exenatide

1 interaction

Monitor/Modify Tx

immune globulin + exenatide

monitor renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity (additive effects)

• factor XIII concentrate
Xembify (immune globulin human-klhw) (immune globulin (human))

+

factor XIII concentrate

1 interaction

Monitor/Modify Tx

immune globulin + factor XIII concentrate

monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

• faricimab
Xembify (immune globulin human-klhw) (immune globulin (human))

+

faricimab

1 interaction

Monitor/Modify Tx

immune globulin + faricimab

monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

• fedratinib
Xembify (immune globulin human-klhw) (immune globulin (human))

+

fedratinib

1 interaction

Monitor/Modify Tx

immune globulin + fedratinib

monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

• fenofibrate
Xembify (immune globulin human-klhw) (immune globulin (human))

+

fenofibrate

1 interaction

Monitor/Modify Tx

immune globulin + fenofibrate

monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

• fenofibric acid
Xembify (immune globulin human-klhw) (immune globulin (human))

+

fenofibric acid

1 interaction

Monitor/Modify Tx

immune globulin + fenofibric acid

monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

• fenoprofen
Xembify (immune globulin human-klhw) (immune globulin (human))

+

fenoprofen

1 interaction

Monitor/Modify Tx

immune globulin + fenoprofen

monitor renal fxn, thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity, thromboembolism (additive effects)

• fitusiran
Xembify (immune globulin human-klhw) (immune globulin (human))

+

fitusiran

1 interaction

Monitor/Modify Tx

immune globulin + fitusiran

monitor antithrombin activity level, thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

• flucytosine
Xembify (immune globulin human-klhw) (immune globulin (human))

+

flucytosine

1 interaction

Monitor/Modify Tx

immune globulin + flucytosine

monitor CBC, renal fxn, flucytosine levels; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. flucytosine levels, risk of myelosuppression, nephrotoxicity, other adverse effects (additive effects)

• flurbiprofen
Xembify (immune globulin human-klhw) (immune globulin (human))

+

flurbiprofen

1 interaction

Monitor/Modify Tx

immune globulin + flurbiprofen

monitor renal fxn, thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible; use lowest effective flurbiprofen dose, shortest effective tx duration: combo may incr. risk of nephrotoxicity, thromboembolism (additive effects)

• follitropin
Xembify (immune globulin human-klhw) (immune globulin (human))

+

follitropin

1 interaction

Monitor/Modify Tx

immune globulin + follitropin

monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

• fosinopril
Xembify (immune globulin human-klhw) (immune globulin (human))

+

fosinopril

1 interaction

Monitor/Modify Tx

immune globulin + fosinopril

monitor renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity (additive effects)

• fruquintinib
Xembify (immune globulin human-klhw) (immune globulin (human))

+

fruquintinib

1 interaction

Monitor/Modify Tx

immune globulin + fruquintinib

monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

• hepatitis B immune globulin
Xembify (immune globulin human-klhw) (immune globulin (human))

+

hepatitis B immune globulin

1 interaction

Monitor/Modify Tx

immune globulin + hepatitis B immune globulin

monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

• hydrochlorothiazide
Xembify (immune globulin human-klhw) (immune globulin (human))

+

hydrochlorothiazide

1 interaction

Monitor/Modify Tx

immune globulin + hydrochlorothiazide

monitor renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity (additive effects)

• ibuprofen
Xembify (immune globulin human-klhw) (immune globulin (human))

+

ibuprofen

1 interaction

Monitor/Modify Tx

immune globulin + ibuprofen

monitor renal fxn, thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible; use lowest effective ibuprofen dose, shortest effective tx duration: combo may incr. risk of nephrotoxicity, thromboembolism (additive effects)

• ibuprofen lysine
Xembify (immune globulin human-klhw) (immune globulin (human))

+

ibuprofen lysine

1 interaction

Monitor/Modify Tx

immune globulin + ibuprofen lysine

monitor renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity (additive effects)

• ifosfamide
Xembify (immune globulin human-klhw) (immune globulin (human))

+

ifosfamide

1 interaction

Monitor/Modify Tx

immune globulin + ifosfamide

monitor CBC, renal, cardiac fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. ifosfamide levels, risk of myelosuppression, serious infection, encephalopathy, nephrotoxicity, cardiotoxicity, other adverse effects (additive effects)

• indapamide
Xembify (immune globulin human-klhw) (immune globulin (human))

+

indapamide

1 interaction

Monitor/Modify Tx

immune globulin + indapamide

monitor renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity (additive effects)

• indomethacin
Xembify (immune globulin human-klhw) (immune globulin (human))

+

indomethacin

1 interaction

Monitor/Modify Tx

immune globulin + indomethacin

monitor renal fxn, thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible; use lowest effective indomethacin dose, shortest effective tx duration: combo may incr. risk of nephrotoxicity, thromboembolism (additive effects)

• iohexol
Xembify (immune globulin human-klhw) (immune globulin (human))

+

iohexol

1 interaction

Monitor/Modify Tx

immune globulin + iohexol

monitor renal fxn, thrombosis s/sx if IV iohexol use; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity, thromboembolism (additive effects)

• iopamidol
Xembify (immune globulin human-klhw) (immune globulin (human))

+

iopamidol

1 interaction

Monitor/Modify Tx

immune globulin + iopamidol

if IV iopamidol use, monitor renal fxn, thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity, thromboembolism (additive effects)

• irbesartan
Xembify (immune globulin human-klhw) (immune globulin (human))

+

irbesartan

1 interaction

Monitor/Modify Tx

immune globulin + irbesartan

monitor renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity (additive effects)

• ketoprofen
Xembify (immune globulin human-klhw) (immune globulin (human))

+

ketoprofen

1 interaction

Monitor/Modify Tx

immune globulin + ketoprofen

monitor renal fxn, thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity, thromboembolism (additive effects)

• ketorolac
Xembify (immune globulin human-klhw) (immune globulin (human))

+

ketorolac

1 interaction

Monitor/Modify Tx

immune globulin + ketorolac

monitor renal fxn, thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible; use lowest effective ketorolac dose, shortest effective tx duration: combo may incr. risk of nephrotoxicity, thromboembolism (additive effects)

• lazertinib
Xembify (immune globulin human-klhw) (immune globulin (human))

+

lazertinib

1 interaction

Monitor/Modify Tx

immune globulin + lazertinib

monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

• lenalidomide
Xembify (immune globulin human-klhw) (immune globulin (human))

+

lenalidomide

1 interaction

Monitor/Modify Tx

immune globulin + lenalidomide

monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

• lenvatinib
Xembify (immune globulin human-klhw) (immune globulin (human))

+

lenvatinib

1 interaction

Monitor/Modify Tx

immune globulin + lenvatinib

monitor renal fxn, thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity, thromboembolism (additive effects)

• levonorgestrel (contraceptive)
Xembify (immune globulin human-klhw) (immune globulin (human))

+

levonorgestrel (contraceptive)

1 interaction

Monitor/Modify Tx

immune globulin + levonorgestrel (contraceptive)

monitor thrombosis s/sx, especially w/ concomitant estrogen use; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

• levonorgestrel (hormone replacement)
Xembify (immune globulin human-klhw) (immune globulin (human))

+

levonorgestrel (hormone replacement)

1 interaction

Monitor/Modify Tx

immune globulin + levonorgestrel (hormone replacement)

monitor thrombosis s/sx, especially w/ concomitant estrogen use; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

• lifileucel
Xembify (immune globulin human-klhw) (immune globulin (human))

+

lifileucel

1 interaction

Monitor/Modify Tx

immune globulin + lifileucel

monitor renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity (additive effects)

• liraglutide
Xembify (immune globulin human-klhw) (immune globulin (human))

+

liraglutide

1 interaction

Monitor/Modify Tx

immune globulin + liraglutide

monitor renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity (additive effects)

• lisinopril
Xembify (immune globulin human-klhw) (immune globulin (human))

+

lisinopril

1 interaction

Monitor/Modify Tx

immune globulin + lisinopril

monitor renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity (additive effects)

• lithium
Xembify (immune globulin human-klhw) (immune globulin (human))

+

lithium

1 interaction

Monitor/Modify Tx

immune globulin + lithium

monitor lithium levels, renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. lithium levels, risk of nephrotoxicity, other adverse effects (additive effects)

• losartan
Xembify (immune globulin human-klhw) (immune globulin (human))

+

losartan

1 interaction

Monitor/Modify Tx

immune globulin + losartan

monitor renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity (additive effects)

• luspatercept
Xembify (immune globulin human-klhw) (immune globulin (human))

+

luspatercept

1 interaction

Monitor/Modify Tx

immune globulin + luspatercept

if beta thalassemia use, monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

• lusutrombopag
Xembify (immune globulin human-klhw) (immune globulin (human))

+

lusutrombopag

1 interaction

Monitor/Modify Tx

immune globulin + lusutrombopag

monitor platelets, thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

• lutetium Lu 177 vipivotide tetraxetan
Xembify (immune globulin human-klhw) (immune globulin (human))

+

lutetium Lu 177 vipivotide tetraxetan

1 interaction

Monitor/Modify Tx

immune globulin + lutetium Lu 177 vipivotide tetraxetan

monitor renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity (additive effects)

• magnesium citrate
Xembify (immune globulin human-klhw) (immune globulin (human))

+

magnesium citrate

1 interaction

Monitor/Modify Tx

immune globulin + magnesium citrate

monitor renal fxn, especially if magnesium citrate bowel prep use; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity (additive effects)

• magnesium salicylate
Xembify (immune globulin human-klhw) (immune globulin (human))

+

magnesium salicylate

1 interaction

Monitor/Modify Tx

immune globulin + magnesium salicylate

monitor renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity (additive effects)

• measles/mumps/rubella vaccine, live
Xembify (immune globulin human-klhw) (immune globulin (human))

+

measles/ mumps/ rubella vaccine, live

1 interaction

Monitor/Modify Tx

immune globulin + measles/ mumps/ rubella vaccine, live

vaccinate at least 2wk before or 8-11mo after IVIG tx; if vaccine given shortly before IVIG, consider re-vaccination: combo may result in inadequate vaccine response (antagonistic effects)

• meclofenamate
Xembify (immune globulin human-klhw) (immune globulin (human))

+

meclofenamate

1 interaction

Monitor/Modify Tx

immune globulin + meclofenamate

monitor renal fxn, thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity, thromboembolism (additive effects)

• medroxyprogesterone (contraceptive)
Xembify (immune globulin human-klhw) (immune globulin (human))

+

medroxyprogesterone (contraceptive)

1 interaction

Monitor/Modify Tx

immune globulin + medroxyprogesterone (contraceptive)

monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

• medroxyprogesterone (hormone replacement)
Xembify (immune globulin human-klhw) (immune globulin (human))

+

medroxyprogesterone (hormone replacement)

1 interaction

Monitor/Modify Tx

immune globulin + medroxyprogesterone (hormone replacement)

monitor thrombosis s/sx, especially w/ concomitant estrogen use; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

• mefenamic acid
Xembify (immune globulin human-klhw) (immune globulin (human))

+

mefenamic acid

1 interaction

Monitor/Modify Tx

immune globulin + mefenamic acid

monitor renal fxn, thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity, thromboembolism (additive effects)

• megestrol
Xembify (immune globulin human-klhw) (immune globulin (human))

+

megestrol

1 interaction

Monitor/Modify Tx

immune globulin + megestrol

monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

• meloxicam
Xembify (immune globulin human-klhw) (immune globulin (human))

+

meloxicam

1 interaction

Monitor/Modify Tx

immune globulin + meloxicam

monitor renal fxn, thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible; use lowest effective meloxicam dose, shortest effective tx duration: combo may incr. risk of nephrotoxicity, thromboembolism (additive effects)

• menotropins
Xembify (immune globulin human-klhw) (immune globulin (human))

+

menotropins

1 interaction

Monitor/Modify Tx

immune globulin + menotropins

monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

• mesalamine
Xembify (immune globulin human-klhw) (immune globulin (human))

+

mesalamine

1 interaction

Monitor/Modify Tx

immune globulin + mesalamine

monitor renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity (additive effects)

• mesalamine rectal
Xembify (immune globulin human-klhw) (immune globulin (human))

+

mesalamine rectal

1 interaction

Monitor/Modify Tx

immune globulin + mesalamine rectal

monitor renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity (additive effects)

• methoxy polyethylene glycol-epoetin beta
Xembify (immune globulin human-klhw) (immune globulin (human))

+

methoxy polyethylene glycol-epoetin beta

1 interaction

Monitor/Modify Tx

immune globulin + methoxy polyethylene glycol-epoetin beta

monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

• methyltestosterone
Xembify (immune globulin human-klhw) (immune globulin (human))

+

methyltestosterone

1 interaction

Monitor/Modify Tx

immune globulin + methyltestosterone

monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

• metolazone
Xembify (immune globulin human-klhw) (immune globulin (human))

+

metolazone

1 interaction

Monitor/Modify Tx

immune globulin + metolazone

monitor renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity (additive effects)

• mitomycin
Xembify (immune globulin human-klhw) (immune globulin (human))

+

mitomycin

1 interaction

Monitor/Modify Tx

immune globulin + mitomycin

monitor renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity (additive effects)

• moexipril
Xembify (immune globulin human-klhw) (immune globulin (human))

+

moexipril

1 interaction

Monitor/Modify Tx

immune globulin + moexipril

monitor renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity (additive effects)

• momelotinib
Xembify (immune globulin human-klhw) (immune globulin (human))

+

momelotinib

1 interaction

Monitor/Modify Tx

immune globulin + momelotinib

monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

• nabumetone
Xembify (immune globulin human-klhw) (immune globulin (human))

+

nabumetone

1 interaction

Monitor/Modify Tx

immune globulin + nabumetone

monitor renal fxn, thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity, thromboembolism (additive effects)

• naproxen
Xembify (immune globulin human-klhw) (immune globulin (human))

+

naproxen

1 interaction

Monitor/Modify Tx

immune globulin + naproxen

monitor renal fxn, thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible; use lowest effective naproxen dose, shortest effective tx duration: combo may incr. risk of nephrotoxicity, thromboembolism (additive effects)

• necitumumab
Xembify (immune globulin human-klhw) (immune globulin (human))

+

necitumumab

1 interaction

Monitor/Modify Tx

immune globulin + necitumumab

monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

• neomycin
Xembify (immune globulin human-klhw) (immune globulin (human))

+

neomycin

1 interaction

Monitor/Modify Tx

immune globulin + neomycin

if compromised gut wall allows for neomycin absorption, monitor renal fxn, ototoxicity; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. neomycin levels, risk of nephrotoxicity, auditory, vestibular, other adverse effects (additive effects)

• nintedanib
Xembify (immune globulin human-klhw) (immune globulin (human))

+

nintedanib

1 interaction

Monitor/Modify Tx

immune globulin + nintedanib

monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

• norelgestromin (contraceptive)
Xembify (immune globulin human-klhw) (immune globulin (human))

+

norelgestromin (contraceptive)

1 interaction

Monitor/Modify Tx

immune globulin + norelgestromin (contraceptive)

monitor thrombosis s/sx, especially w/ concomitant estrogen use; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

• norethindrone (contraceptive)
Xembify (immune globulin human-klhw) (immune globulin (human))

+

norethindrone (contraceptive)

1 interaction

Monitor/Modify Tx

immune globulin + norethindrone (contraceptive)

monitor thrombosis s/sx, especially w/ concomitant estrogen use; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

• norethindrone acetate (hormone replacement)
Xembify (immune globulin human-klhw) (immune globulin (human))

+

norethindrone acetate (hormone replacement)

1 interaction

Monitor/Modify Tx

immune globulin + norethindrone acetate (hormone replacement)

monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

• norgestimate (contraceptive)
Xembify (immune globulin human-klhw) (immune globulin (human))

+

norgestimate (contraceptive)

1 interaction

Monitor/Modify Tx

immune globulin + norgestimate (contraceptive)

monitor thrombosis s/sx, especially w/ concomitant estrogen use; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

• norgestimate (hormone replacement)
Xembify (immune globulin human-klhw) (immune globulin (human))

+

norgestimate (hormone replacement)

1 interaction

Monitor/Modify Tx

immune globulin + norgestimate (hormone replacement)

monitor thrombosis s/sx, especially w/ concomitant estrogen use; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

• norgestrel (contraceptive)
Xembify (immune globulin human-klhw) (immune globulin (human))

+

norgestrel (contraceptive)

1 interaction

Monitor/Modify Tx

immune globulin + norgestrel (contraceptive)

monitor thrombosis s/sx, especially w/ concomitant estrogen use; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

• nusinersen
Xembify (immune globulin human-klhw) (immune globulin (human))

+

nusinersen

1 interaction

Monitor/Modify Tx

immune globulin + nusinersen

monitor renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity (additive effects)

• olaparib
Xembify (immune globulin human-klhw) (immune globulin (human))

+

olaparib

1 interaction

Monitor/Modify Tx

immune globulin + olaparib

monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

• olmesartan medoxomil
Xembify (immune globulin human-klhw) (immune globulin (human))

+

olmesartan medoxomil

1 interaction

Monitor/Modify Tx

immune globulin + olmesartan medoxomil

monitor renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity (additive effects)

• olsalazine
Xembify (immune globulin human-klhw) (immune globulin (human))

+

olsalazine

1 interaction

Monitor/Modify Tx

immune globulin + olsalazine

monitor renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity (additive effects)

• ospemifene
Xembify (immune globulin human-klhw) (immune globulin (human))

+

ospemifene

1 interaction

Monitor/Modify Tx

immune globulin + ospemifene

monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

• oxaprozin
Xembify (immune globulin human-klhw) (immune globulin (human))

+

oxaprozin

1 interaction

Monitor/Modify Tx

immune globulin + oxaprozin

monitor renal fxn, thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity, thromboembolism (additive effects)

• pacritinib
Xembify (immune globulin human-klhw) (immune globulin (human))

+

pacritinib

1 interaction

Monitor/Modify Tx

immune globulin + pacritinib

monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

• pamidronate
Xembify (immune globulin human-klhw) (immune globulin (human))

+

pamidronate

1 interaction

Monitor/Modify Tx

immune globulin + pamidronate

monitor renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. pamidronate levels, risk of nephrotoxicity, other adverse effects (additive effects)

• paromomycin
Xembify (immune globulin human-klhw) (immune globulin (human))

+

paromomycin

1 interaction

Monitor/Modify Tx

immune globulin + paromomycin

if compromised gut wall allows for paromomycin absorption, monitor renal fxn, ototoxicity; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. paromomycin levels, risk of nephrotoxicity, auditory, vestibular, other adverse effects (additive effects)

• pazopanib
Xembify (immune globulin human-klhw) (immune globulin (human))

+

pazopanib

1 interaction

Monitor/Modify Tx

immune globulin + pazopanib

monitor renal fxn, thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity, thromboembolism (additive effects)

• pegaspargase
Xembify (immune globulin human-klhw) (immune globulin (human))

+

pegaspargase

1 interaction

Monitor/Modify Tx

immune globulin + pegaspargase

monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

• pemetrexed
Xembify (immune globulin human-klhw) (immune globulin (human))

+

pemetrexed

1 interaction

Monitor/Modify Tx

immune globulin + pemetrexed

monitor CBC, renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. pemetrexed levels, risk of myelosuppression, nephrotoxicity, other adverse effects (additive effects)

• penicillamine
Xembify (immune globulin human-klhw) (immune globulin (human))

+

penicillamine

1 interaction

Monitor/Modify Tx

immune globulin + penicillamine

monitor CBC, renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. penicillamine levels, risk of myelosuppression, nephrotoxicity, other adverse effects (additive effects)

• pentostatin
Xembify (immune globulin human-klhw) (immune globulin (human))

+

pentostatin

1 interaction

Monitor/Modify Tx

immune globulin + pentostatin

monitor CBC, renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. pentostatin levels, risk of serious infection, myelosuppression, nephrotoxicity, other adverse effects (additive effects)

• perindopril
Xembify (immune globulin human-klhw) (immune globulin (human))

+

perindopril

1 interaction

Monitor/Modify Tx

immune globulin + perindopril

monitor renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity (additive effects)

• piroxicam
Xembify (immune globulin human-klhw) (immune globulin (human))

+

piroxicam

1 interaction

Monitor/Modify Tx

immune globulin + piroxicam

monitor renal fxn, thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible; use lowest effective piroxicam dose, shortest effective tx duration: combo may incr. risk of nephrotoxicity, thromboembolism (additive effects)

• plazomicin
Xembify (immune globulin human-klhw) (immune globulin (human))

+

plazomicin

1 interaction

Monitor/Modify Tx

immune globulin + plazomicin

monitor plazomicin levels, renal fxn, ototoxicity; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. plazomicin levels, risk of nephrotoxicity, auditory, vestibular, other adverse effects (additive effects)

• polyethylene glycol
Xembify (immune globulin human-klhw) (immune globulin (human))

+

polyethylene glycol

1 interaction

Monitor/Modify Tx

immune globulin + polyethylene glycol

monitor renal fxn, especially if polyethylene glycol bowel prep use; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity (additive effects)

• polyethylene glycol/electrolytes
Xembify (immune globulin human-klhw) (immune globulin (human))

+

polyethylene glycol/ electrolytes

1 interaction

Monitor/Modify Tx

immune globulin + polyethylene glycol/ electrolytes

monitor renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity (additive effects)

• pomalidomide
Xembify (immune globulin human-klhw) (immune globulin (human))

+

pomalidomide

1 interaction

Monitor/Modify Tx

immune globulin + pomalidomide

monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

• ponatinib
Xembify (immune globulin human-klhw) (immune globulin (human))

+

ponatinib

1 interaction

Monitor/Modify Tx

immune globulin + ponatinib

monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

• porfimer
Xembify (immune globulin human-klhw) (immune globulin (human))

+

porfimer

1 interaction

Monitor/Modify Tx

immune globulin + porfimer

monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

• progesterone (hormone replacement)
Xembify (immune globulin human-klhw) (immune globulin (human))

+

progesterone (hormone replacement)

1 interaction

Monitor/Modify Tx

immune globulin + progesterone (hormone replacement)

monitor thrombosis s/sx, especially w/ concomitant estrogen use; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

• progesterone vaginal (hormone replacement)
Xembify (immune globulin human-klhw) (immune globulin (human))

+

progesterone vaginal (hormone replacement)

1 interaction

Monitor/Modify Tx

immune globulin + progesterone vaginal (hormone replacement)

monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

• prothrombin complex concentrate (human)
Xembify (immune globulin human-klhw) (immune globulin (human))

+

prothrombin complex concentrate (human)

1 interaction

Monitor/Modify Tx

immune globulin + prothrombin complex concentrate (human)

monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

• quinapril
Xembify (immune globulin human-klhw) (immune globulin (human))

+

quinapril

1 interaction

Monitor/Modify Tx

immune globulin + quinapril

monitor renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity (additive effects)

• raloxifene
Xembify (immune globulin human-klhw) (immune globulin (human))

+

raloxifene

1 interaction

Monitor/Modify Tx

immune globulin + raloxifene

monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

• ramipril
Xembify (immune globulin human-klhw) (immune globulin (human))

+

ramipril

1 interaction

Monitor/Modify Tx

immune globulin + ramipril

monitor renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity (additive effects)

• ramucirumab
Xembify (immune globulin human-klhw) (immune globulin (human))

+

ramucirumab

1 interaction

Monitor/Modify Tx

immune globulin + ramucirumab

monitor renal fxn, thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity, thromboembolism (additive effects)

• ranibizumab
Xembify (immune globulin human-klhw) (immune globulin (human))

+

ranibizumab

1 interaction

Monitor/Modify Tx

immune globulin + ranibizumab

monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible; risk may be lower if ocular implant use: combo may incr. risk of thromboembolism (additive effects)

• ravulizumab
Xembify (immune globulin human-klhw) (immune globulin (human))

+

ravulizumab

1 interaction

Monitor/Modify Tx

immune globulin + ravulizumab

admin. supplemental 600 mg ravulizumab dose w/in 4h of immune globulin cycle completion: combo may decr. ravulizumab levels, efficacy (FcRn blockade)

• Rho(D) immune globulin
Xembify (immune globulin human-klhw) (immune globulin (human))

+

Rho(D) immune globulin

1 interaction

Monitor/Modify Tx

immune globulin + Rho(D) immune globulin

monitor renal fxn, thrombosis s/sx; use lowest effective dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity, thromboembolism (additive effects)

• ritlecitinib
Xembify (immune globulin human-klhw) (immune globulin (human))

+

ritlecitinib

1 interaction

Monitor/Modify Tx

immune globulin + ritlecitinib

monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

• rituximab
Xembify (immune globulin human-klhw) (immune globulin (human))

+

rituximab

1 interaction

Monitor/Modify Tx

immune globulin + rituximab

monitor renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity (additive effects)

• romiplostim
Xembify (immune globulin human-klhw) (immune globulin (human))

+

romiplostim

1 interaction

Monitor/Modify Tx

immune globulin + romiplostim

monitor platelets, thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

• ropeginterferon alfa-2b
Xembify (immune globulin human-klhw) (immune globulin (human))

+

ropeginterferon alfa-2b

1 interaction

Monitor/Modify Tx

immune globulin + ropeginterferon alfa-2b

monitor renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity (additive effects)

• ruxolitinib
Xembify (immune globulin human-klhw) (immune globulin (human))

+

ruxolitinib

1 interaction

Monitor/Modify Tx

immune globulin + ruxolitinib

monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

• ruxolitinib topical
Xembify (immune globulin human-klhw) (immune globulin (human))

+

ruxolitinib topical

1 interaction

Monitor/Modify Tx

immune globulin + ruxolitinib topical

monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

• salsalate
Xembify (immune globulin human-klhw) (immune globulin (human))

+

salsalate

1 interaction

Monitor/Modify Tx

immune globulin + salsalate

monitor renal fxn, thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity, thromboembolism (additive effects)

• segesterone (contraceptive)
Xembify (immune globulin human-klhw) (immune globulin (human))

+

segesterone (contraceptive)

1 interaction

Monitor/Modify Tx

immune globulin + segesterone (contraceptive)

monitor thrombosis s/sx, especially w/ concomitant estrogen use; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

• sipuleucel-T
Xembify (immune globulin human-klhw) (immune globulin (human))

+

sipuleucel-T

1 interaction

Monitor/Modify Tx

immune globulin + sipuleucel-T

monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

• sirolimus
Xembify (immune globulin human-klhw) (immune globulin (human))

+

sirolimus

1 interaction

Monitor/Modify Tx

immune globulin + sirolimus

monitor renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity (additive effects)

• sitagliptin
Xembify (immune globulin human-klhw) (immune globulin (human))

+

sitagliptin

1 interaction

Monitor/Modify Tx

immune globulin + sitagliptin

monitor renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity (additive effects)

• sodium tetradecyl sulfate
Xembify (immune globulin human-klhw) (immune globulin (human))

+

sodium tetradecyl sulfate

1 interaction

Monitor/Modify Tx

immune globulin + sodium tetradecyl sulfate

monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

• sotatercept
Xembify (immune globulin human-klhw) (immune globulin (human))

+

sotatercept

1 interaction

Monitor/Modify Tx

immune globulin + sotatercept

monitor Hgb, thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

• sparsentan
Xembify (immune globulin human-klhw) (immune globulin (human))

+

sparsentan

1 interaction

Monitor/Modify Tx

immune globulin + sparsentan

monitor renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity (additive effects)

• spironolactone
Xembify (immune globulin human-klhw) (immune globulin (human))

+

spironolactone

1 interaction

Monitor/Modify Tx

immune globulin + spironolactone

monitor renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity (additive effects)

• sulfate bowel prep
Xembify (immune globulin human-klhw) (immune globulin (human))

+

sulfate bowel prep

1 interaction

Monitor/Modify Tx

immune globulin + sulfate bowel prep

monitor renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity (additive effects)

• sulindac
Xembify (immune globulin human-klhw) (immune globulin (human))

+

sulindac

1 interaction

Monitor/Modify Tx

immune globulin + sulindac

monitor renal fxn, thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity, thromboembolism (additive effects)

• sunitinib
Xembify (immune globulin human-klhw) (immune globulin (human))

+

sunitinib

1 interaction

Monitor/Modify Tx

immune globulin + sunitinib

monitor renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity (additive effects)

• tacrolimus
Xembify (immune globulin human-klhw) (immune globulin (human))

+

tacrolimus

1 interaction

Monitor/Modify Tx

immune globulin + tacrolimus

monitor tacrolimus levels, renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. tacrolimus levels, risk of nephrotoxicity, other adverse effects (additive effects)

• tamoxifen
Xembify (immune globulin human-klhw) (immune globulin (human))

+

tamoxifen

1 interaction

Monitor/Modify Tx

immune globulin + tamoxifen

monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

• telavancin
Xembify (immune globulin human-klhw) (immune globulin (human))

+

telavancin

1 interaction

Monitor/Modify Tx

immune globulin + telavancin

monitor ECG, renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. telavancin levels, risk of QT prolongation, cardiac arrhythmias, nephrotoxicity, other adverse effects (additive effects)

• telmisartan
Xembify (immune globulin human-klhw) (immune globulin (human))

+

telmisartan

1 interaction

Monitor/Modify Tx

immune globulin + telmisartan

monitor renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity (additive effects)

• temsirolimus
Xembify (immune globulin human-klhw) (immune globulin (human))

+

temsirolimus

1 interaction

Monitor/Modify Tx

immune globulin + temsirolimus

monitor renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity (additive effects)

• tenofovir alafenamide
Xembify (immune globulin human-klhw) (immune globulin (human))

+

tenofovir alafenamide

1 interaction

Monitor/Modify Tx

immune globulin + tenofovir alafenamide

monitor renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. tenofovir levels, risk of nephrotoxicity, other adverse effects (additive effects)

• testosterone
Xembify (immune globulin human-klhw) (immune globulin (human))

+

testosterone

1 interaction

Monitor/Modify Tx

immune globulin + testosterone

monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

• thalidomide
Xembify (immune globulin human-klhw) (immune globulin (human))

+

thalidomide

1 interaction

Monitor/Modify Tx

immune globulin + thalidomide

monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

• tiopronin
Xembify (immune globulin human-klhw) (immune globulin (human))

+

tiopronin

1 interaction

Monitor/Modify Tx

immune globulin + tiopronin

monitor renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity (additive effects)

• tivozanib
Xembify (immune globulin human-klhw) (immune globulin (human))

+

tivozanib

1 interaction

Monitor/Modify Tx

immune globulin + tivozanib

monitor renal fxn, thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity, thromboembolism (additive effects)

• tofacitinib
Xembify (immune globulin human-klhw) (immune globulin (human))

+

tofacitinib

1 interaction

Monitor/Modify Tx

immune globulin + tofacitinib

monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

• tolmetin
Xembify (immune globulin human-klhw) (immune globulin (human))

+

tolmetin

1 interaction

Monitor/Modify Tx

immune globulin + tolmetin

monitor renal fxn, thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity, thromboembolism (additive effects)

• toremifene
Xembify (immune globulin human-klhw) (immune globulin (human))

+

toremifene

1 interaction

Monitor/Modify Tx

immune globulin + toremifene

monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

• trametinib
Xembify (immune globulin human-klhw) (immune globulin (human))

+

trametinib

1 interaction

Monitor/Modify Tx

immune globulin + trametinib

monitor thrombosis s/sx, especially in combo w/ dabrafenib; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

• trandolapril
Xembify (immune globulin human-klhw) (immune globulin (human))

+

trandolapril

1 interaction

Monitor/Modify Tx

immune globulin + trandolapril

monitor renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity (additive effects)

• tretinoin
Xembify (immune globulin human-klhw) (immune globulin (human))

+

tretinoin

1 interaction

Monitor/Modify Tx

immune globulin + tretinoin

monitor thrombosis s/sx, especially during 1st month of tretinoin use; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

• triamterene
Xembify (immune globulin human-klhw) (immune globulin (human))

+

triamterene

1 interaction

Monitor/Modify Tx

immune globulin + triamterene

monitor renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity (additive effects)

• upadacitinib
Xembify (immune globulin human-klhw) (immune globulin (human))

+

upadacitinib

1 interaction

Monitor/Modify Tx

immune globulin + upadacitinib

monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

• vadadustat
Xembify (immune globulin human-klhw) (immune globulin (human))

+

vadadustat

1 interaction

Monitor/Modify Tx

immune globulin + vadadustat

monitor Hgb, thrombosis s/sx; use lowest effective vadadustat dose, immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

• valacyclovir
Xembify (immune globulin human-klhw) (immune globulin (human))

+

valacyclovir

1 interaction

Monitor/Modify Tx

immune globulin + valacyclovir

monitor renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. acyclovir levels, risk of nephrotoxicity, other adverse effects (additive effects)

• valoctocogene roxaparvovec
Xembify (immune globulin human-klhw) (immune globulin (human))

+

valoctocogene roxaparvovec

1 interaction

Monitor/Modify Tx

immune globulin + valoctocogene roxaparvovec

monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

• valsartan
Xembify (immune globulin human-klhw) (immune globulin (human))

+

valsartan

1 interaction

Monitor/Modify Tx

immune globulin + valsartan

monitor renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity (additive effects)

• vamorolone
Xembify (immune globulin human-klhw) (immune globulin (human))

+

vamorolone

1 interaction

Monitor/Modify Tx

immune globulin + vamorolone

monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

• vancomycin
Xembify (immune globulin human-klhw) (immune globulin (human))

+

vancomycin

1 interaction

Monitor/Modify Tx

immune globulin + vancomycin

use lowest immune globulin dose, concentration and infusion rate possible; VANCOMYCIN IV: monitor renal fxn, vancomycin levels, ototoxicity; VANCOMYCIN PO: consider monitoring renal fxn, vancomycin levels, ototoxicity in pts w/ severe renal impairment, severe intestinal inflammation, or prolonged course >2 g/day: combo may incr. vancomycin levels, risk of nephrotoxicity, auditory, vestibular, other adverse effects (additive effects; incr. oral vancomycin absorption if inflamed or compromised gut mucosa)

• varicella vaccine, live
Xembify (immune globulin human-klhw) (immune globulin (human))

+

varicella vaccine, live

1 interaction

Monitor/Modify Tx

immune globulin + varicella vaccine, live

vaccinate at least 2wk before or 8-11mo after IVIG tx; if vaccine given shortly before IVIG, consider re-vaccination: combo may result in inadequate vaccine response (antagonistic effects)

• varicella zoster immune globulin
Xembify (immune globulin human-klhw) (immune globulin (human))

+

varicella zoster immune globulin

1 interaction

Monitor/Modify Tx

immune globulin + varicella zoster immune globulin

monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

• voclosporin
Xembify (immune globulin human-klhw) (immune globulin (human))

+

voclosporin

1 interaction

Monitor/Modify Tx

immune globulin + voclosporin

monitor renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity (additive effects)

• von Willebrand factor
Xembify (immune globulin human-klhw) (immune globulin (human))

+

von Willebrand factor

1 interaction

Monitor/Modify Tx

immune globulin + von Willebrand factor

monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

• vorinostat
Xembify (immune globulin human-klhw) (immune globulin (human))

+

vorinostat

1 interaction

Monitor/Modify Tx

immune globulin + vorinostat

monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

• ziv-aflibercept
Xembify (immune globulin human-klhw) (immune globulin (human))

+

ziv-aflibercept

1 interaction

Monitor/Modify Tx

immune globulin + ziv-aflibercept

monitor renal fxn, thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity, thromboembolism (additive effects)

• zoledronic acid
Xembify (immune globulin human-klhw) (immune globulin (human))

+

zoledronic acid

1 interaction

Monitor/Modify Tx

immune globulin + zoledronic acid

monitor renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. zoledronic acid levels, risk of nephrotoxicity, other adverse effects (additive effects)

• zonisamide
Xembify (immune globulin human-klhw) (immune globulin (human))

+

zonisamide

1 interaction

Monitor/Modify Tx

immune globulin + zonisamide

monitor renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity (additive effects)